Goldman Sachs price target lowered to $550 from $585 at Citi
Citi lowered the firm’s price target on Goldman Sachs (GS) to $550 from $585 and keeps a Neutral rating on the shares. The firm revised U.S.
pharmaphorum23h
Teva, Sanofi score well with anti-TL1A drug in IBD test
Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...